Literature DB >> 2293247

Treatment of depression in the elderly: a Canadian view.

R J Ancill1, S G Holliday.   

Abstract

1. Between 10 and 15% of people over the age of 65 have a potentially treatable depression. 2. The commonest antidepressants used in Canada, the tertiary-amine tricyclics, are potentially problematic when used with geriatric patients. 3. It is current practice in geriatric psychiatry to use secondary-amine tricyclics as "first choice" drugs for elderly depressed patients. 4. Electroconvulsive therapy can be effectively used to deal with severely depressed elderly patients, particularly if there are also features of dementia. 5. Although "better drugs" are needed for the elderly, people over the age of 65 are typically excluded from treatment outcome research.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293247     DOI: 10.1016/0278-5846(90)90036-g

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  3 in total

Review 1.  Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?

Authors:  V Ozdemir; J Fourie; U Busto; C A Naranjo
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

2.  Test-Retest Reliability and Minimal Detectable Change of Four Cognitive Tests in Community-Dwelling Older Adults.

Authors:  Katherine L Webb; Joanne Ryan; Rory Wolfe; Robyn L Woods; Raj C Shah; Anne M Murray; Suzanne G Orchard; Elsdon Storey
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

3.  Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults.

Authors:  Mohammadreza Mohebbi; Van Nguyen; John J McNeil; Robyn L Woods; Mark R Nelson; Raj C Shah; Elsdon Storey; Anne M Murray; Christopher M Reid; Brenda Kirpach; Rory Wolfe; Jessica E Lockery; Michael Berk
Journal:  Gen Hosp Psychiatry       Date:  2017-08-18       Impact factor: 3.238

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.